BioCentury | Mar 2, 2021
Product Development

Investors act early as pharmacodynamic data drive Morphic shares

With pharmacodynamic data driving a gain of over $1.6 billion in market cap, Morphic is the latest example of how deep insights into structural biology are pushing clinical inflection points earlier.  Shares of Morphic Holding Inc....
BioCentury | Jan 30, 2021
Regulation

Novartis subcutaneous mAb for MS, Incyte and Karyopharm oral cancer therapies backed by CHMP

Among the therapies to receive a positive opinion from EMA’s CHMP in January were drugs from Novartis, Incyte and Karyopharm that have convenient routes of administration.  The agency backed Kesimpta ofatumumab, an auto-injectable anti-CD20 mAb from Novartis AG (NYSE:NVS; SIX:NOVN),...
BioCentury | Aug 28, 2020
Deals

BARDA enlisting start-ups in fight against COVID-19 via JLABS collaboration

A collaboration between JLABS and BARDA gives the government agency access to start-ups that it needs to fast track new, innovative COVID-19 therapies and diagnostics it otherwise would struggle...
BioCentury | Jul 11, 2020
Translation in Brief

Peptide blocker of myeloid checkpoint; plus a magnet-based device to collect circulating tumor cells, severe vs. mild COVID-19 immune cell profiles and more

...tissue University of Colorado Anschutz Medical Campus and Arca biopharma Inc. (NASDAQ:ABIO) researchers have suggested CD49e...
...JACC: Basic to Translational Science , found that ACE2, the host receptor for SARS-CoV-2, and CD49e...
...in COVID-19 patients with underlying heart disorders. Targets ACE2 - Angiotensin-converting enzyme 2 CD49e - Integrin alpha(5)...
BioCentury | Jun 3, 2020
Finance

Third Rock-launched Pliant is latest biotech to climb on public debut

Pliant joins a slew of recent biotechs that have seen substantial first-day gains. The fibrosis company closed up $5.30 (33%) to $21.30 on Wednesday after raising $144 million through the sale of 9 million shares...
BioCentury | Mar 3, 2020
Finance

Pliant to advance rare fibrosis pipeline with Novartis-led $100M C round

A $100 million series C round led by Novartis and backed by multiple crossover investors gives Third Rock-founded Pliant ample cash to push forward with multiple fibrosis programs. The cash bolus comes less than half...
BioCentury | Oct 28, 2019

CD49e/CD61 inhibition for breast cancer and melanoma

...DISEASE CATEGORY: Cancer INDICATION: Breast cancer; melanoma Inhibition of CD49e/CD61 alone or in combination with anti-PD-1...
...or in combination with anti-PD-1 therapies could treat breast cancer and melanoma. An siRNA against CD49e/CD61...
...humanized mAb against CD49e/CD61, in Phase II testing for diabetic nephropathy. TARGET/MARKER/PATHWAY: Integrin α 5β3 (CD49e/CD61...
BioCentury | Oct 25, 2019
Product Development

Deciding factors in the shifting MS treatment landscape

The efficacy and convenience advantages that established oral medicines as the go-to therapy in multiple sclerosis are the same factors now squeezing them out. Two years post-launch, the success of injectable Ocrevus ocrelizumab from Roche...
BioCentury | Oct 23, 2019
Company News

Pliant to flesh out fibrosis pipeline after NASH deal with Novartis

Pliant’s deal to out-license its NASH candidate to Novartis for $80 million will allow the fibrosis company to fund development of its lead candidate, as well as advance its preclinical pipeline. Novartis AG (NYSE:NVS; SIX:NOVN)...
BioCentury | Sep 19, 2019
Product Development

Anokion puts liver to the test

Data presented Sept. 13 at a major multiple sclerosis meeting showcased the ability of Anokion’s liver targeting technology to induce immune tolerance. Armed with a fresh $40 million series B round, Anokion S.A. is developing...
Items per page:
1 - 10 of 694